![InFocus Therapeutics accepted into Berkeley SkyDeck’s Batch 18 Pad-13 Incubator Program](/static/87fa9b7a5d7a4b06f3c59c77c45d37ce/51a07/unnamed.jpg)
InFocus was selected amongst over 1,300 startups into the prestigious Berkeley SkyDeck Pad-13 Program. Our CSO will represent the company to join the three-months program starting in May 2024. As a Pad-13 member, the InFocus team receives exclusive access to world-class resources from the SkyDeck Program as well as the faculty and alumni network of UC Berkeley.